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LETTERS
One Flu for One 
Health
To the Editor: The emergence 
and spread of inﬂ  uenza A pandemic 
(H1N1) 2009 virus from the animal 
reservoir to humans raise questions 
about the future approach to inﬂ  uenza 
virus infections. The scientiﬁ  c commu-
nity has evidence demonstrating that 
inﬂ   uenza virus genes migrate across 
continents and animal species and as-
semble themselves in combinations 
that are a threat to animal and human 
health, resulting in panzootics like that 
caused by inﬂ  uenza A virus (H5N1) 
or pandemics like that caused by pan-
demic (H1N1) 2009 virus. The latter 
virus emerged from the animal reser-
voir, containing a unique combination 
of genes donated by viruses originat-
ing from 3 species and 2 hemispheres. 
In a globalized environment, mapping 
gene movement across species and 
national borders and identifying muta-
tions and gene constellations with pan-
demic potential or virulence determi-
nants are essential to enact prevention 
and control strategies at a global level. 
This conclusion is in agreement with, 
and possibly the best example of, the 
One Health  (http://un-inﬂ  uenza.org/
node/2341) vision: a multidisciplinary 
collaborative approach to improving 
the health of humans, animals, and the 
environment. One Health is endorsed 
by the United Nations Food and Ag-
riculture Organization, the World Or-
ganisation for Animal Health, and the 
World Health Organization. 
Vast improvements in capacity 
building have been achieved as a re-
sult of the inﬂ  uenza A (H5N1) global 
crisis. Thousands of viral isolates with 
zoonotic potential have been obtained 
through surveillance efforts, although 
the genetic information has not been 
exploited fully. In addition, investigat-
ing how inﬂ  uenza viruses circulate in 
certain species, including dogs, pigs, 
and horses, has been neglected. This 
neglect is evidenced by the fact that, 
at the time of this writing, GenBank 
contained 4,001 full genome sequenc-
es of inﬂ  uenza viruses isolated from 
humans, 2,590 of viruses isolated 
from birds, and only 325 from swine, 
85 from horses, 2 from mink, 4 from 
dogs, 2 from cats, 2 from tigers, and 3 
from seals. 
We invite donors and interna-
tional agencies to invest in a novel 
approach to inﬂ  uenza virus infections, 
to abandon preﬁ  xed  compartments 
linked to geographic origin or species 
of isolation, and to analyze the inﬂ  u-
enza gene pool as one entity. We pro-
pose capitalizing on existing achieve-
ments and investments to develop an 
international network and a permanent 
observatory, which will improve our 
understanding of the dynamics of the 
inﬂ  uenza virus gene pool in animals 
and humans. A greater understanding 
will generate important information to 
support both public and animal health. 
Ideally, a small consortium, including 
representatives of major international 
organizations, could take leadership 
and liaise with major institutions in-
volved in inﬂ  uenza surveillance and 
research to develop a feasibility study 
and roadmap to achieve this goal. The 
One Flu initiative could result in in-
ternational synergies, the bridging of 
gaps between medical and veterinary 
scientists, permanent monitoring of 
virus evolution and epidemiology, and 
the best exploitation of investments in 
capacity building. Above all, this col-
laboration could be a challenge and op-
portunity to implement the One Health 
vision, and possibly act as a model for 
other emerging zoonotic diseases.
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Pandemic (H1N1) 
2009 Risk for 
Nurses after 
Trivalent 
Vaccination
To the Editor: We report results 
of the effect of inactivated seasonal 
inﬂ  uenza vaccination on risk of pan-
demic (H1N1) 2009 in a cohort of 
nurses in Canada who participated in a 
recent randomized controlled trial that 
compared the effectiveness of surgical 
masks with that of N95 respirators in 
preventing inﬂ  uenza  (1). From Sep-
tember 23, 2008, through December 8, 
2008, a total of 446 nurses from 8 hos-
pitals in the province of Ontario were 
enrolled. They were then randomly 
assigned an intervention; 225 were as-
signed to wear surgical masks, and 221 
were assigned to wear the N95 respira-
tor. The mean age of participants was 
36.2 years; 94% were women. A total 
of 128 (30.3%) received the trivalent 
inﬂ  uenza vaccine. Vaccination status 
was similar between the groups: 68 
(30.2%) persons in the surgical mask 
group and 62 (28.1%) persons in the 
N95 respirator group had received the 
2008–2009 trivalent inactivated inﬂ  u-
enza vaccine. The nurses were moni-
tored from January 12, 2009, through 
April 23, 2009.
Blood specimens for serologic 
analysis were obtained before enroll-
ment and at the end of the follow-up 
period. End-of-study serum samples 
were collected from April 23 through 
May 15, 2009. Serologic infection 
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was deﬁ  ned by a >4-fold increase in 
inﬂ  uenza-speciﬁ  c hemagglutinin inhi-
bition assay titer between baseline and 
convalescent-phase serum samples 
by using turkey erythrocytes and A/
TN/1560/2009(H1N1), a representa-
tive pandemic inﬂ  uenza virus.
Of the 422 nurses included in the 
analysis, 42 (10.0%) showed serocon-
version to pandemic (H1N1) 2009. Of 
128 nurses who received the trivalent 
inﬂ   uenza vaccine, 9 (7.0%) showed 
seroconversion vs. 33 (11.2%) of 
those that did not (relative risk 0.63, 
95% conﬁ  dence interval 0.31–1.27, p 
= 0.19).
Although the point estimate was 
protective, the conﬁ  dence interval is 
wide and does not exclude an increase 
in risk. Our sample size limits infer-
ences that can be drawn. Heterotypic 
antibodies may have contributed to the 
relatively high rate of seroconversion. 
A rise in antibody titer is considered 
by some as an outcome associated 
with bias, unlike virus identiﬁ  cation.   
Nevertheless, these data suggest a pos-
sible positive effect of seasonal inﬂ  u-
enza vaccine reducing risk of infection 
with pandemic (H1N1) 2009.
This study was funded by the Public 
Health Agency of Canada.
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Patients with 
Pandemic (H1N1) 
2009 in Intensive 
Care Units, Israel
To the Editor: We report re-
sults of an active surveillance system 
established by the Tel Aviv District 
Health Ofﬁ  ce in Israel. This surveil-
lance system monitors the daily status 
of patients with laboratory-conﬁ  rmed 
pandemic (H1N1) 2009 virus infec-
tion in each of the district’s intensive 
care units (ICUs), including pediatric 
ICUs.
Follow-up is maintained by daily 
phone conversations with medical 
staff until disease outcome is con-
cluded by discharge, transfer to a 
long-term rehabilitation facility, or 
death. Medical records, as well as 
daily laboratory reports, are collected 
to conﬁ  rm or to rule out pandemic 
(H1N1) 2009 infection.
During July 10–October 10, 
2009, our prospective cohort included 
17 patients with pandemic (H1N1) 
2009 laboratory-conﬁ  rmed  infection 
who were residents of the district; 12 
(70.6%) were male patients. The me-
dian age was 44 years (interquartile 
range 13–72 years). By October 10, 
2009, six patients had been discharged, 
7 had died, 2 had been transferred to 
long-term rehabilitation facilities, and 
2 remained hospitalized.
Twelve (70.6%) patients had an 
underlying medical condition, mainly 
chronic lung disease (6 patients) or 
chronic cardiovascular disease (5 pa-
tients). Two patients were morbidly 
obese (body mass index >35), and 1 
patient was pregnant. Additionally, 3 
patients (17.6%) were infected while 
hospitalized. 
Thirteen patients (76.5%) had 
acute respiratory distress syndrome 
caused by diffuse viral pneumonitis. 
Other notable manifestations were 
acute renal failure (6 patients), sepsis/
septic shock (5 patients), and neuro-
logic complications such as Guillain-
Barré syndrome, encephalitis, and sei-
zures (3 patients). 
Documented nosocomial sepsis, 
often of multiple gram-negative bacte-
ria (9 patients), was the most frequent 
complication during the course of the 
disease. Other frequent characteristics 
were the use of high positive end-ex-
piratory pressure during mechanical 
ventilation (4 patients) and the need 
for tracheostomy (5 patients).
Average time from disease on-
set to hospital admission was 3 days. 
Time from hospital admission to ICU 
admission for those patients who died 
was longer than for those who sur-
vived, with a median of 2 days com-
pared with 0.5 day, respectively, al-
beit not signiﬁ  cant (p = 0.26). Average 
hospitalization was 23.4 days; average 
length of stay in the ICU was 16.7 
days (71.4% of the average hospital-
ization time).
As mentioned previously, 7 pa-
tients (41.2%) died; 5 (71.4%) were 
male, similar to their cohort’s pro-
portion. One signiﬁ  cant difference (p 
= 0.02) was found between the age 
of survivors (mean 26.0 years, 95% 
conﬁ  dence interval 7.6–44.3) and the 
age of nonsurvivors (mean 59.3 years, 
95% conﬁ   dence interval 39.6–79.0). 
The most prominent case–fatality rate 
was for elderly patients, >65 years of 
age (3 of 4 patients) followed by pa-
tients between 20 and 64 years of age 
(4 of 9 patients); these subgroups con-
stituted 23.5% and 52.9% of the co-
hort, respectively.
Estimated incidence rate was 13.8 
patients and 5.7 deaths in ICUs per 
million residents in the Tel Aviv dis-
trict. Again, the elderly subgroup was 
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